At METUPUK, we campaign for new and better therapies for patients with secondary breast cancer. One of our recent campaigns, #TrodelvyNow helped to make a new type of drug, Trodelvy (sacituzumab govitecan) available for SBC patients in the UK. Scientist and METUPUK volunteer, Helen, explains how Trodelvy works and why it’s important that more drugs like this get to patients urgently.
Oh how I wished it was a walking journey! That I could deal with! But in the last 6 months my oncologist’s quest to get me to have this PIKC3A targeted drug, was admirable, and left us on a roller coaster of emotions.
METUPUK historically maintained their own in-house clinical trial database for metastatic trials in the UK as there was no one source that contained them all. It used the key sites used across the UK; Cancer Research UK, Be Part of Research, ISRCTN and ClinicalTrials.gov.
Leaping forward to 2022, surely by now one of them must be THE accurate, easily searchable source of breast cancer trials? If not, how do our oncologists quickly and accurately find the best trials for their metastatic patients?
And where do patients start when looking for a metastatic trial themselves?
METUPUK are delighted by the Scottish Medicines Consortium (SMC) acceptance of Enhertu (trastuzumab deruxtecan) for routine use on the NHS. The Scottish Medicines Consortium (SMC) has accepted: Trastuzumab deruxtecan (Enhertu)
‘The Darker Side of Pink’ was launched in Breast Cancer Awareness Month 2021 by METUPUK – the UK’s only patient advocacy group dedicated to Metastatic (Secondary) Breast Cancer (MBC) –
METUPUK are devastated by the news that one of our Trustees and friend Connie Johncock has died. Connie was a founder trustee of METUPUK and our Treasurer, overseeing our finances as we
Hi. My name is Gita and I have been a Therapeutic Radiographer for nearly 30 years. I’d like to share my professional and personal experiences of treating both primary and secondary breast cancer.
The Scottish Medicines Consortium (SMC) have decided against funding the metastatic breast cancer drug alpelisib (Piqray).
We had to confirm back on the 5th November the heartbreaking news that the wonderful Philippa Hetherington had died 💔
She was an absolute force of intellectual nature for breast cancer in general, not just Inflammatory Breast Cancer.
Did you know that the Trodelvy campaign in England for TNBC was HER campaign?
METUPUK are delighted for the approval of Trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults who have received one or more prior anti-HER2 based therapies approved for use through the Cancer Drugs Fund in NHS in England.
